Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia, Mixed Dyslipidemia
Trial Timeline
Apr 22, 2022 → Nov 17, 2022
NCT ID
NCT05546398About Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab
Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab is a pre-clinical stage product being developed by Daiichi Sankyo for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05546398. Target conditions include Hypercholesterolemia, Mixed Dyslipidemia.
What happened to similar drugs?
20 of 20 similar drugs in Hypercholesterolemia were approved
Approved (20) Terminated (2) Active (0)
✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05546398 | Pre-clinical | Completed |
Competing Products
20 competing products in Hypercholesterolemia